AZD5305

Phase 2Small molecule

AstraZeneca

AZD5305 is one of 140 small molecule programs targeting Metastatic Prostate Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

139

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Prostate CancerActive, not recruiting

Prostate CancerRecruiting

Ovarian CancerActive, not recruiting

RadiotherapyRecruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Prostate CancerPreclinical

Recruiting

Ovarian CancerPreclinical

Active, not recruiting

RadiotherapyPhase 1

Recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

48 2

Talzenna

Pfizer

Phase 3

7 3

Acetylsalicylic Acid

Bayer

Phase 3

2 4

GM-CSF

YY-mAbs Therapeutics

Phase 3

8 5

Xaluritamig

Amgen

Phase 3

4 6

Radium-223

Bayer

Phase 3

6 7

Gallium Ga 68 Gozetotide

MMayo Clinic

Phase 3

3 8

AZD5305

AstraZeneca

Phase 2

1 9

Trexall

Jazz Pharmaceuticals

Preclinical

—10

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalActive, not recruiting

Ovarian Cancer

NCT04644068

Q1 2028

Phase 1Recruiting

Radiotherapy

NCT04550104

Q2 2031

PreclinicalActive, not recruiting

Metastatic Prostate Cancer

NCT05367440

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT05573724·16 enrolled

Radiotherapy1 trial

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Recruiting·UUniversity of Leeds·Phase 1·NCT04550104·200 enrolled

Prostate Cancer1 trial

A Phase I/II, Modular, Open-Label, Multi-Centre Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD9750 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Metastatic Prostate Cancer (ANDROMEDA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT07336446·6 enrolled

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Preclinical·NCT04644068·702 enrolled

Metastatic Prostate Cancer1 trial

A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Preclinical·NCT05367440·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AZD5305. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD5305 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD5305. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD5305

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2028

Q2 2031

Trials by Indication[1]

Advanced Solid Malignancies1 trial

Radiotherapy1 trial

Prostate Cancer1 trial

Ovarian Cancer1 trial

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News